Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors

Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug Delivery System 2020/03/25, Vol.35(2), pp.137-145
Hauptverfasser: Andoh, Tooru, Ichikawa, Hideki, Fujimoto, Takuya, Suzuki, Minoru
Format: Artikel
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 145
container_issue 2
container_start_page 137
container_title Drug Delivery System
container_volume 35
creator Andoh, Tooru
Ichikawa, Hideki
Fujimoto, Takuya
Suzuki, Minoru
description Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.
doi_str_mv 10.2745/dds.35.137
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419470119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419470119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</originalsourceid><addsrcrecordid>eNo9kE1Lw0AQhhdRsFYv_oIFb0LqfmST7MGDFL-g4EXPyyTZbVPSbJzdIP57t7T2NDDvM-_AQ8gtZwtR5uqhbcNCqgWX5RmZ8arimSilOCczprnMFGPFJbkKYctYnkI-I7icEO0QaYgQp0BhaOnoY9p00FPv6GCniH6gDYxxQkvjxiKMvxQSm8IfGtFC3O0r_Bi7RDqPdAd9tx5g3-tdpLELYUq3085juCYXDvpgb45zTr5enj-Xb9nq4_V9-bTKGiFkmakGnFTa1oIVUNR5W1SV0y1UkksQ0KS81q3O67LhqlCVKnOmpcyVk4Kr0sk5uTv0jui_Jxui2foJh_TSiJzrvGSc60TdH6gGfQhonRmx2wH-Gs7M3qlJTo1UJjlN8OMB3iZda3tCAWPX9PYfFUf-tG82gMYO8g8QFYHM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419470119</pqid></control><display><type>article</type><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</creator><creatorcontrib>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</creatorcontrib><description>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</description><identifier>ISSN: 0913-5006</identifier><identifier>EISSN: 1881-2732</identifier><identifier>DOI: 10.2745/dds.35.137</identifier><language>eng ; jpn</language><publisher>Kawasaki: THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</publisher><subject>Alpha rays ; Anticancer properties ; Boron ; Cancer ; Cancer therapies ; Gadolinium ; Gadolinium isotopes ; Health services ; Irradiation ; Neutrons ; Nuclear capture ; Phenylalanine ; Radiation ; Radiation therapy ; Reagents ; Sarcoma ; Soft tissue sarcoma ; Soft tissues ; Thermal neutrons ; Tissues ; Tumor cells ; Tumors</subject><ispartof>Drug Delivery System, 2020/03/25, Vol.35(2), pp.137-145</ispartof><rights>2020 The Japan Society of Drug Delivery System</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids></links><search><creatorcontrib>Andoh, Tooru</creatorcontrib><creatorcontrib>Ichikawa, Hideki</creatorcontrib><creatorcontrib>Fujimoto, Takuya</creatorcontrib><creatorcontrib>Suzuki, Minoru</creatorcontrib><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><title>Drug Delivery System</title><addtitle>DDS</addtitle><description>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</description><subject>Alpha rays</subject><subject>Anticancer properties</subject><subject>Boron</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Gadolinium</subject><subject>Gadolinium isotopes</subject><subject>Health services</subject><subject>Irradiation</subject><subject>Neutrons</subject><subject>Nuclear capture</subject><subject>Phenylalanine</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Reagents</subject><subject>Sarcoma</subject><subject>Soft tissue sarcoma</subject><subject>Soft tissues</subject><subject>Thermal neutrons</subject><subject>Tissues</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0913-5006</issn><issn>1881-2732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kE1Lw0AQhhdRsFYv_oIFb0LqfmST7MGDFL-g4EXPyyTZbVPSbJzdIP57t7T2NDDvM-_AQ8gtZwtR5uqhbcNCqgWX5RmZ8arimSilOCczprnMFGPFJbkKYctYnkI-I7icEO0QaYgQp0BhaOnoY9p00FPv6GCniH6gDYxxQkvjxiKMvxQSm8IfGtFC3O0r_Bi7RDqPdAd9tx5g3-tdpLELYUq3085juCYXDvpgb45zTr5enj-Xb9nq4_V9-bTKGiFkmakGnFTa1oIVUNR5W1SV0y1UkksQ0KS81q3O67LhqlCVKnOmpcyVk4Kr0sk5uTv0jui_Jxui2foJh_TSiJzrvGSc60TdH6gGfQhonRmx2wH-Gs7M3qlJTo1UJjlN8OMB3iZda3tCAWPX9PYfFUf-tG82gMYO8g8QFYHM</recordid><startdate>20200325</startdate><enddate>20200325</enddate><creator>Andoh, Tooru</creator><creator>Ichikawa, Hideki</creator><creator>Fujimoto, Takuya</creator><creator>Suzuki, Minoru</creator><general>THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</general><general>Japan Science and Technology Agency</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20200325</creationdate><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><author>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>Alpha rays</topic><topic>Anticancer properties</topic><topic>Boron</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Gadolinium</topic><topic>Gadolinium isotopes</topic><topic>Health services</topic><topic>Irradiation</topic><topic>Neutrons</topic><topic>Nuclear capture</topic><topic>Phenylalanine</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Reagents</topic><topic>Sarcoma</topic><topic>Soft tissue sarcoma</topic><topic>Soft tissues</topic><topic>Thermal neutrons</topic><topic>Tissues</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Andoh, Tooru</creatorcontrib><creatorcontrib>Ichikawa, Hideki</creatorcontrib><creatorcontrib>Fujimoto, Takuya</creatorcontrib><creatorcontrib>Suzuki, Minoru</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug Delivery System</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andoh, Tooru</au><au>Ichikawa, Hideki</au><au>Fujimoto, Takuya</au><au>Suzuki, Minoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</atitle><jtitle>Drug Delivery System</jtitle><addtitle>DDS</addtitle><date>2020-03-25</date><risdate>2020</risdate><volume>35</volume><issue>2</issue><spage>137</spage><epage>145</epage><pages>137-145</pages><issn>0913-5006</issn><eissn>1881-2732</eissn><abstract>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</abstract><cop>Kawasaki</cop><pub>THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</pub><doi>10.2745/dds.35.137</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0913-5006
ispartof Drug Delivery System, 2020/03/25, Vol.35(2), pp.137-145
issn 0913-5006
1881-2732
language eng ; jpn
recordid cdi_proquest_journals_2419470119
source J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Alpha rays
Anticancer properties
Boron
Cancer
Cancer therapies
Gadolinium
Gadolinium isotopes
Health services
Irradiation
Neutrons
Nuclear capture
Phenylalanine
Radiation
Radiation therapy
Reagents
Sarcoma
Soft tissue sarcoma
Soft tissues
Thermal neutrons
Tissues
Tumor cells
Tumors
title Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A11%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20and%20potential%20of%20neutron%20capture%20therapy%20as%20a%20new%20treatment%20option%20for%20malignant%20soft%20tissue%20tumors&rft.jtitle=Drug%20Delivery%20System&rft.au=Andoh,%20Tooru&rft.date=2020-03-25&rft.volume=35&rft.issue=2&rft.spage=137&rft.epage=145&rft.pages=137-145&rft.issn=0913-5006&rft.eissn=1881-2732&rft_id=info:doi/10.2745/dds.35.137&rft_dat=%3Cproquest_cross%3E2419470119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419470119&rft_id=info:pmid/&rfr_iscdi=true